WASHINGTON — Sen. Bill Cassidy is the rare Republican who has long been open to drug pricing reforms, espousing the virtues of value-based payment arrangements and his home state’s newfangled “Netflix” model for funding hepatitis treatments.

As Cassidy has pushed for reforms, however, the rest of his party’s position on the issue has shifted under his feet, largely thanks to the Trump administration’s unpredictable and aggressive stance on efforts to lower drug costs. President Trump has espoused, for example, a far-reaching proposal to use foreign prices to cap some payments for drugs in the U.S.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy